Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines.

By G. Curigliano, D. Cardinale, Thomas M. Suter, G. Plataniotis, E. Azambuja, M. Sandri, C. Criscitiello, A. Goldhirsch, C. Cipolla, F. Roila. Annals of Oncology, 2012

845 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Oncology

View Paper: https://www.semanticscholar.org/paper/24c20913d7bdb4f636d4181085de211eb639221e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. I. Graham
2. T. Ivanova
3. J. Herrmann
4. Jose Luis Zamorano
5. D. Lenihan
6. P. Lancellotti

In Oncology

1. R. Siegel
2. A. Jemal
3. K. Miller
4. Julia H. Rowland
5. T. Ivanova
6. J. Herrmann
7. A. Mariotto
8. F. Bray

Citations in the corpus

• Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations (2020, background): “Therefore, screening with an LVEF assessment should be considered at 6e12 months, and possibly 2 years post-treatment, and consideration for reassessment periodically thereafter.(13,62,177) It is accepted that the increased risk of LVD is lifelong and tends to increase proportionally with the total ”
• Cancer treatment and survivorship statistics, 2016 (2016, background): “Anthracyclines and HER-2–targeted drugs can lead to cardiomyopathy and congestive heart failure.(36) Treatment with aromatase inhibitors, which is generally reserved for postmenopausal women, can also cause osteoporosis, as well as myalgia and arthralgia,(37) whereas tamoxifen treatment slightly inc”
• American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline (2016, neutral): “anthracycline, as has been detailed by the European Society for Medical Oncology.(73) Aromatase inhibitors can raise cholesterol levels(74,75) and the risk of diabetes.”
• Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. (2014, background): “Cardiotoxicity is defined as an LVEF decline of $5% to <55% with heart failure symptoms or an asymptomatic decrease of LVEF $10% to <55% (59).”
• Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics (2022, background): “The majority of chemotherapeutic agents affect these tissues in a dose-dependent manner; though, there are differences in their sensitivity to individuals due to enormous factors such as metabolism efficiency, genetic makeup, other medication, and environmental factors (Table 2).(174) Despite enormo”
• 2016 European Guidelines on cardiovascular disease prevention in clinical practice (2016, background): “A targeted approach to treat patients with early LV dysfunction, in combination with global longitudinal strain abnormalities and biomarker (notably troponin) elevation, has been proposed.(173,174) In the case of a decrease in LV function during or after chemotherapy, the use of cardiotoxic agents s”
• 2016 European Guidelines on cardiovascular disease prevention in clinical practice (2017, neutral): “A targeted approach to treat patients with early LV dysfunction, in combination with global longitudinal strain abnormalities and biomarker (notably troponin) elevation, has been proposed [173, 174].”
• 2016 European Guidelines on cardiovascular disease prevention in clinical practice. (2016, background): “A targeted approach to treat patients with early LV dysfunction, in combination with global longitudinal strain abnormalities and biomarker (notably troponin) elevation, has been proposed.(173,174) In the case of a decrease in LV function during or after chemotherapy, the use of cardiotoxic agents s”